Climb Bio (NASDAQ:CLYM – Get Free Report) and Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.
Earnings & Valuation
This table compares Climb Bio and Viridian Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Climb Bio | N/A | N/A | -$59.85 million | ($0.78) | -13.53 |
| Viridian Therapeutics | $70.85 million | 22.96 | -$342.60 million | ($3.32) | -4.75 |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Climb Bio and Viridian Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Climb Bio | 1 | 0 | 9 | 3 | 3.08 |
| Viridian Therapeutics | 1 | 1 | 12 | 0 | 2.79 |
Climb Bio currently has a consensus target price of $20.30, indicating a potential upside of 92.42%. Viridian Therapeutics has a consensus target price of $36.14, indicating a potential upside of 129.04%. Given Viridian Therapeutics’ higher probable upside, analysts plainly believe Viridian Therapeutics is more favorable than Climb Bio.
Volatility & Risk
Climb Bio has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.
Profitability
This table compares Climb Bio and Viridian Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Climb Bio | N/A | -31.45% | -30.39% |
| Viridian Therapeutics | -490.31% | -80.19% | -48.84% |
Insider and Institutional Ownership
69.8% of Climb Bio shares are held by institutional investors. 2.6% of Climb Bio shares are held by company insiders. Comparatively, 2.4% of Viridian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Climb Bio beats Viridian Therapeutics on 9 of the 14 factors compared between the two stocks.
About Climb Bio
Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.
About Viridian Therapeutics
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
